New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
05:55 EDTVSTM, VSTM, ONCY, ONCY, RIGL, RIGL, CELG, CELG, OXBT, OXBT, GALE, GALE, GTXI, GTXI, AFFY, AFFYBiotech Industry Organization to host a conference
15th Annual BIO CEO & Investor Conference is being held in New York on February 11-12.
News For CELG;OXBT;GALE;GTXI;AFFY;VSTM;ONCY;RIGL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 23, 2015
09:25 EDTRIGLOn The Fly: Pre-market Movers
Subscribe for More Information
08:15 EDTRIGLRigel Pharmaceuticals and Bristol-Myers announces R&D collaboration agreement
Rigel Pharmaceuticals (RIGL) and Bristol-Myers (BMY) announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors. TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body. The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune system's activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Bristol-Myers Squibb's Opdivo and Yervoy. Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize small molecule therapeutics derived from Rigel's TGF beta library, including, but not limited to, those approved to treat cancer. Bristol-Myers Squibb will pay $30M upfront and Rigel will be eligible to receive development and regulatory milestones that could total more than $309M for a successful compound approved in multiple indications. Rigel will also be eligible to receive tiered royalties on the net sales of any products from the collaboration.
08:06 EDTRIGLBristol-Myers, Rigel enter R&D agreement for TGF beta receptor kinase inhibitors
Rigel Pharmaceuticals (RIGL) and Bristol-Myers Squibb (BMY) announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigelís extensive portfolio of small molecule TGF beta receptor kinase inhibitors. TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body. The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune systemís activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Bristol-Myers Squibbís Opdivo, or nivolumab, and Yervoy, or ipilimumab. Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize small molecule therapeutics derived from Rigelís TGF beta library, including, but not limited to, those approved to treat cancer. Bristol-Myers Squibb will pay $30M upfront and Rigel will be eligible to receive development and regulatory milestones that could total more than $309M for a successful compound approved in multiple indications. Rigel will also be eligible to receive tiered royalties on the net sales of any products from the collaboration.
February 20, 2015
16:03 EDTCELGOptions Update; February 20, 2015
Subscribe for More Information
09:38 EDTCELGActive equity options trading on open
Subscribe for More Information
05:27 EDTCELGCelgene Revlimid approved by EC
Subscribe for More Information
February 18, 2015
16:00 EDTCELGOptions Update; February 18, 2015
Subscribe for More Information
10:05 EDTCELGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:38 EDTCELGCelgene reports FDA expands indication for Revlimid combo
Subscribe for More Information
09:37 EDTCELGOption volume leaders on open
Option volume leaders: AAPL TSLA TWTR CELG APO NFLX AXP APA LNKD C GILD according to Track Data.
06:47 EDTCELGCelgene initiated with a Buy at Canaccord
Target $156.
06:41 EDTONCYOncolytics Biotech completes enrollment of randomized Phase II study of REOLYSIN
Subscribe for More Information
06:37 EDTONCYOncolytics Biotech completes enrollment in Phase II colorectal cancer study
Subscribe for More Information
February 17, 2015
07:04 EDTGTXIGTx names Robert Wills as executive chairman
Subscribe for More Information
06:40 EDTONCYOncolytics Biotech receives ODD from FDA for REOLYSIN
Subscribe for More Information
06:36 EDTONCYOncolytics Biotech granted Orphan Drug Designation for REOLYSIN by FDA
Oncolytics Biotech announced that the FDA has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of pancreatic cancer. REOLYSIN is Oncolytics' proprietary isolate of the reovirus. Its primary mode of activity is to infect and selectively target tumours with activating Ras pathway mutations and/or over-expressions of Ras pathway elements including, amongst others, EGFR, BRAF and KRAS.
February 13, 2015
14:04 EDTONCYOncolytics Biotech treatment of pancreatic cancer gets FDA orphan designation
According to a post on the FDA's website, Oncolytics Biotech's treatment of pancreatic cancer, Reolysin, was granted orphan designation. Reference Link
11:04 EDTVSTMVerastem receives orphan status for treatment of ovarian cancer
The granted Verastem orphan status for defactinib, its treatment of ovarian cancer.
08:19 EDTCELGAckman noncommittal on McDonald's rumors, Bloomberg reports
Subscribe for More Information
05:38 EDTCELGCelgene volatility increases on wide price movement
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use